Vælg den region, der bedst passer til din placering eller dine præferencer.
Denne indstilling styrer sproget for brugergrænsefladen, inklusive knapper, menuer og al tekst på webstedet. Vælg dit foretrukne sprog for den bedste browsingoplevelse.
Vælg de sprog for jobannoncer, du vil se. Denne indstilling afgør, hvilke jobannoncer der vises for dig.
The Laboratory for Disease Mechanisms in Cancer, led by Prof. Kim De Keersmaecker at KU Leuven, is seeking a highly motivated postdoc to investigate how ribosomal protein (RP) gene defects drive cancer development and response to therapy.
Mutations and deletions affecting ribosomal proteins occur across a wide range of hematological malignancies and solid tumors. Through the ERC-funded RIBOCANCER program, our group has pioneered the study of cancer-associated ribosomal protein mutations, showing that these defects can
promote malignant transformation through selective rewiring of gene expression programs. However, several open questions remain on the mechanisms through which RP defects contribute to cancer initiation, progression, and therapeutic response.
Using integrated translatome, proteome, and structural analyses, we demonstrated that leukemia-associated RPL10 and RPS15 mutations induce codon-specific translation defects that rewire downstream transcriptional programs (Kampen et al., Nature Communications, 2019; Astier and Caruso et al., HemaSphere, 2026). The successful candidate will build on this foundation to identify mechanistic dependencies and therapeutic opportunities in RP-deficient cancers using state-of-the-art technologies such as Ribo-seq, proteomics and CRISPR-based functional genomics on cancer cell and mouse models.
Translational Perspective
We aim to translate fundamental insights into ribosome dysfunction into novel strategies for cancer treatment. The candidate will investigate how RP defects influence drug sensitivity, stress response pathways, and tumor evolution, with the aim of identifying biomarkers and therapeutic vulnerabilities that can be exploited clinically.
The project offers a unique opportunity to work at the interface of cancer genetics, ribosome biology, and translational oncology. Findings from this work are expected to provide new insights into the treatment of cancers carrying ribosomal protein alterations and contribute to the development of precision medicine approaches for these patients.
Research Environment
Our laboratory studies the genetic and molecular mechanisms underlying hematological malignancies and cancer development. We value a collaborative and supportive working environment that encourages scientific discussion and teamwork. We are part of a vibrant and highly interactive research environment within the Department of Oncology and the Leuven Cancer Institute (LKI) at KU Leuven, uniting cancer clinicians and researchers. KU Leuven consistently ranks among Europe's leading universities and offers an international, collaborative, and stimulating scientific environment.
The successful candidate will benefit from being hosted in a multidisciplinary research team that has extensive collaborations with experts in cancer genomics, hematology, RNA biology, translational control, and bioinformatics, as well as access to state-of-the-art core facilities for genomics, proteomics, imaging, flow cytometry, and animal research.
Website unit
We are looking for a highly motivated and creative scientist meeting the following criteria:
Essential qualifications
Additional major assets
A funded 1-year postdoc position with possibility of extension for 2 years provided a positive evaluation after 1 year. The successful candidate will also be encouraged and will get full support to obtain independent fellowships (Marie-Curie, EMBO, or National funding organizations).
Starting date: To be negotiated, any date after September 15th 2026.
For more information please contact Prof. dr. Kim De Keersmaecker, mail: [email protected].
Only applications submitted via the tool will be considered. They will be reviewed on a continuous basis, and the position will remain open until a suitable candidate has been identified.
KU Leuven strives for an inclusive, respectful and socially safe environment. We embrace diversity among individuals and groups as an asset. Open dialogue and differences in perspective are essential for an ambitious research and educational environment. In our commitment to equal opportunity, we recognize the consequences of historical inequalities. We do not accept any form of discrimination based on, but not limited to, gender identity and expression, sexual orientation, age, ethnic or national background, skin colour, religious and philosophical diversity, neurodivergence, employment disability, health, or socioeconomic status. For questions about accessibility or support offered, we are happy to assist you at this email address.
KU Leuven is an autonomous university. It was founded in 1425. It was born of and has grown within the Catholic tradition.
Besøg arbejdsgiverens side